NewAmsterdam Pharma Co NV (NAMS)
16.23
+0.40
(+2.53%)
USD |
NASDAQ |
Sep 27, 16:00
16.26
+0.04
(+0.22%)
After-Hours: 20:00
NewAmsterdam Pharma Revenue (Quarterly): 2.279M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.279M |
| March 31, 2024 | 1.401M |
| Date | Value |
|---|---|
| June 30, 2023 | 1.717M |
| March 31, 2023 | 8.629M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.401M
Minimum
Mar 2024
8.629M
Maximum
Mar 2023
3.506M
Average
1.998M
Median
Revenue (Quarterly) Benchmarks
| Koninklijke Philips NV | 4.495B |
| uniQure NV | 11.13M |
| ProQR Therapeutics NV | 6.789M |
| Merus NV | 7.332M |
| argenx SE | 477.64M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -39.01M |
| Total Expenses (Quarterly) | 53.68M |
| EPS Diluted (Quarterly) | -0.41 |
| Enterprise Value | 1.030B |
| Profit Margin (Quarterly) | -1.71K% |
| Earnings Yield | -15.10% |
| Normalized Earnings Yield | -12.51 |